The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Chronic liver disease (CLD) is a growing cause of morbidity and mortality worldwide. The burden of CLD varies according to etiology and geographic location. We assessed the global burden of disability from the most important complications of CLD (cirrhosis and liver cancer [LC]) according to the most common etiologies between 2007 and 2017. We obtained years living with disability (YLD), years of life lost (YLL), and disability‐adjusted life‐years (DALYs) data from the Global Burden of Disease 2017 study. Between 2007 and 2017, LC DALYs decreased by 4.52% and cirrhosis DALYs decreased by 10.58%. Nevertheless, in 2017, CLD caused 62.16 million DALYs (33.4% LC and 66.5% cirrhosis), of which 96.8% came from YLL (34.1% LC and 65.9% cirrhosis) and 3.2% from YLD (11.6% LC and 88.4% cirrhosis). In 2017, Asia accounted for 66% of all DALYs globally. Central Asia, Africa regions, Southeast Asia, and Eastern Europe had the highest liver‐related DALYs (≥1,000 per 100,000), whereas the lowest rates (≤500 per 100,000) were seen in high‐income regions, such as Asia Pacific, North America, Western Europe, and Australasia. In 2007, hepatitis B virus caused the majority (47.5%) of liver‐related DALYs, followed by hepatitis C virus (23.7%), alcoholic liver disease (14.2%), and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) (6.4%). In 2017, these rates shifted to 45.7%, 24.1%, 4.8%, and 7.1%, respectively. Between 2007 and 2017, cirrhosis‐related DALYs due to NAFLD/NASH increased by 23.4%, whereas the increment was 37.5% for LC‐related DALYs due to NAFLD/NASH. Conclusion: DALYs due to viral hepatitis still account for the largest proportion of CLD‐related DALYs. Although DALYs from all other liver diseases have remained stable in the last decade, DALYs related to NAFLD/NASH are growing. National, regional, and global policies are needed to address the disability burden of NAFLD across the world.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Roth, G. A., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32203-7 · Cited by 8,600
Sepanlou, S. G., Safiri, S., Bisignano, C., Ikuta, K. S., Merat, S., Saberifiroozi, M., Poustchi, H., Tsoi, D., Colombara, D. V., Abdoli, A., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30349-8 · Cited by 1,714
Mokdad (2018) · doi:10.1001/jama.2018.0158 · Cited by 1,517
GBD 2010: design, definitions, and metrics
Murray, C. J., Ezzati, M., Flaxman, A. D., Lim, S., Lozano, R., Michaud, C., Naghavi, M., Salomon, J. A., Shibuya, K., Vos, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61899-6 · Cited by 1,103 · cited 1×
“(18) For administrative and data analysis purposes, the world was split into 21 GBD regions and seven GBD super regions according to epidemiologic similarities and geographic proximity(19) (Supporting Table S3).”
MethodYounossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802
Self-citationMittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.019 · Cited by 648 · cited 1×
“In this context, understanding the global burden of complications of CLD (cirrhosis and LC) according to etiology of CLD, geographic location, and trends over time will be important.(8) Although there are adequate data on the prevalence and mortality associated with CLD, data on morbidity and DALYs related to CLD are…”
BackgroundAlgorithms for enhancing public health utility of national causes-of-death data
Naghavi, M., Makela, S., Foreman, K., O'Brien, J., Pourmalek, F., & Lozano, R. (2010) · Population Health Metrics · doi:10.1186/1478-7954-8-9 · Cited by 440
Liver Cirrhosis Mortality in Europe, with Special Attention to Central and Eastern Europe
Zatoński, W. A., Sulkowska, U., Mańczuk, M., Rehm, J., Boffetta, P., Lowenfels, A. B., & La Vecchia, C. (2010) · European Addiction Research · doi:10.1159/000317248 · Cited by 181 · cited 1×
“In Western Europe, the driver for cirrhosis DALYs was ALD whereas it was HCV in high-income North America, and this finding was consistent with previous knowledge.(32) It is well known that HCV has been the leading cause of cirrhosis, LC, and liver transplantation in the United States for decades.”
Result
Cited by
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
“[1] The subsequent data from the Global Burden of Disease (GBD) study have supplemented this data and provided evidence that NAFLD is the most rapidly increasing global contributor to the disease burden related to the complications of CLD, including cirrhosis and liver cancer.[2,3] Furthermore, the most recent data fr…”
MethodSelf-citationCurrent status and future trends of the global burden of MASLD
Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.02.007 · Cited by 781
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.002 · Cited by 711
Le, M. H., Yeo, Y. H., Zou, B., Barnet, S., Henry, L., Cheung, R., & Nguyen, M. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0239 · Cited by 357
Younossi, Z. M., Paik, J. M., Stepanova, M., Ong, J., Alqahtani, S., & Henry, L. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.01.014 · Cited by 321
Self-citation
Metadata
- Authors
- Paik, J. M., Golabi, P., Younossi, Y., Srishord, M., Mishra, A., & Younossi, Z. M.
- Venue
- Hepatology Communications
- Published
- 2020-09-14
- Volume
- 4
- Issue
- 12
- Pages
- 1769-1780
- ISSN
- 2471-254X (ISSN-L)
- OpenAlex
- W3084955164
- Cited by
- 103
- References
- 10
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017. https://app.cochat.ai/papers/10.1002/hep4.1599
- The paper
- Paik, J. M., Golabi, P., Younossi, Y., Srishord, M., Mishra, A., & Younossi, Z. M. (2020). The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017. Hepatology Communications. https://doi.org/10.1002/hep4.1599
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.